Advances in Pulmonary Nanopharmacology

The field of nanotechnology has revealed unique aptitudes in the manufacture of novel and effective drugs/delivery systems for pulmonary diseases. This knowledge bargains numerous profits in the treatment of chronic human pulmonary diseases with targeted drugs/delivery systems. In recent years, numerous approaches have been reported to transport drugs to the lungs. Delivery of the drugs/delivery systems over the pulmonary way can be prescribed in two ways: oral inhalation and intranasal administration. In nanomaterial-based aerosol inhalation systems, drug delivery to the lungs can be accomplished by repeated high-dose inhalation. New tools deal with major clinical profits to increase the efficiency of pulmonary drug delivery and target specific areas of the lung. Factors such as size distribution, surface charge, quantitative analysis of lipid composition, drug loading rate, and formulation stability are vital in nanomaterials-based nanopharmacology. The alteration from in vitro phase to the clinical stage and production step for nanomaterials is a multipart action with requirements to overcome various limitations. In the present chapter, we focus on new progress in pulmonary nanopharmacology and the supporting approaches for designing new nanomaterials for this arena. Some patents have been gathered about this topic as well. The future viewpoints have also been discoursed.